- Home
- THFF vs PHAR Comparison
THFF vs PHAR Comparison
Compare THFF & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THFF | PHAR |
|---|---|---|
| Founded | 1984 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 686.6M | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | THFF | PHAR |
|---|---|---|
| Price | $62.41 | $17.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $60.00 | $38.00 |
| AVG Volume (30 Days) | ★ 57.4K | 23.0K |
| Earning Date | 02-03-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | ★ 69.68 | N/A |
| EPS | ★ 6.25 | 0.00 |
| Revenue | $250,755,000.00 | ★ $362,274,000.00 |
| Revenue This Year | $33.24 | $25.19 |
| Revenue Next Year | $8.15 | $4.47 |
| P/E Ratio | ★ $10.13 | $3,089.47 |
| Revenue Growth | ★ 31.89 | 26.78 |
| 52 Week Low | $42.05 | $7.50 |
| 52 Week High | $65.79 | $18.12 |
Technical Indicators
Market Signals| Indicator | THFF | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 56.13 | 55.74 |
| Support Level | $64.27 | $16.15 |
| Resistance Level | $65.79 | $17.00 |
| Average True Range (ATR) | 1.30 | 0.76 |
| MACD | -0.15 | -0.05 |
| Stochastic Oscillator | 41.28 | 63.42 |
Price Performance
Historical ComparisonAbout THFF First Financial Corporation Indiana
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.